Developing Small Molecule Therapeutics for the Initial and Adjunctive Treatment of Snakebite

Figure 3

Hypothetical pipeline of SMTs for snakebite treatment. (a) Targeted inhibition of major snake venom enzymatic toxins, secreted phospholipase A2 (sPLA₂), and metallo- and serine-proteases (svMP and SP), through a combination of multiple inhibitory small molecules. (b) In combination with biologicals or others as adjuncts to antivenom for hospital administration (e.g., for targeting non-enzymatic toxins, such as 3-FTX).

(a)

(b)